Erasca Inc（ERAS）の株式分析ERASErasca Inc

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Erasca Inc (ERAS) is a good buy right now, trading at $18.03 with a recent RSI of 46.059, indicating it is not overbought. The stock has shown a remarkable year-to-date change of +402.23% and a one-year change of +1026.88%, reflecting strong momentum. Additionally, the recent FDA Fast Track Designation for ERAS-0015 enhances its growth prospects, which is a significant positive catalyst. However, the company reported a substantial net income loss of -$183,440,000 in Q1 2026, which is a key risk to consider.